Bio-Rad Laboratories, Inc. (BIO)

Bio-Rad Laboratories, Inc. (BIO) is a healthcare company (medical devices) based in the United States. The share price is $359.15, down 0.31% on the day, which values the company at $9.66B. Price as of 17 Nov 2026, 18:19 UTC, from Yahoo Finance.

Key facts

Share price
$359.15−0.31% today
Market value
$9.66B
P/E ratio
9.5×last 12 months
Forward P/E
36.3×
Funk Score
38/100
Against its own history
Below its usual priceusual price $465.05
200-week average
$325.5910% above
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Bio-Rad Laboratories, Inc. in more detail

BIO trades at 9.5× its last twelve months' earnings, 36.3× next year's expected earnings, 3.7× sales. Measured against its own history, the price is 23% below what its usual multiples would imply ($465.05) — below its usual price. It sits 10% above its 200-week average of $325.59.

Over the last five fiscal years Bio-Rad Laboratories, Inc. has compounded revenue 0.3% a year, earnings per share -26.1% a year, free cash flow -4.7% a year. Its Funk Score is 38 out of 100 (financial strength 5.4, profitability 3.3, growth 1.1, value 5.2, each out of 10).

In its favour: Altman Z in the safe zone; Share count keeps falling. Worth checking: Low return on invested capital.

3 of the superinvestors tracked here hold BIO, including John Rogers (3.1% of the portfolio), Matthew McLennan (1.5% of the portfolio), Steven Romick (1.2% of the portfolio).

Superinvestors holding BIO

3 of the investors tracked here report a position in their latest 13F filing.

Compare

Health Care companies of similar size

Side by side:BIO vs PCVX (Bio-Rad Laboratories, Inc. vs Vaxcyte)BIO vs MOH (Bio-Rad Laboratories, Inc. vs Molina Healthcare)BIO vs ENSG (Bio-Rad Laboratories, Inc. vs Ensign Group)BIO vs SYRE (Bio-Rad Laboratories, Inc. vs Spyre Therapeutics)BIO vs QGEN (Bio-Rad Laboratories, Inc. vs Qiagen)

All health care companies by market valueLargest companies in the United StatesAll stocks A–Z

Bio-Rad Laboratories, Inc. (BIO): questions and answers

What is BIO's P/E ratio?

Bio-Rad Laboratories, Inc. trades at 9.5× its last twelve months' earnings and 36.3× next year's expected earnings. At its fiscal year-ends over the past 15 years the P/E ranged from 4.6× to 207.1×, with a median of 18.5×.

What is BIO's PEG ratio?

Bio-Rad Laboratories, Inc.'s PEG ratio is 4.01 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.

What is Bio-Rad Laboratories, Inc.'s market cap?

Bio-Rad Laboratories, Inc. is valued at $9.66B at a share price of $359.15.

Is BIO overvalued or undervalued?

Against its own history, BIO is below its usual price: the price is 23% below the $465.05 implied by the median multiples it has traded at (price / earnings, price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is BIO above its 200-week moving average?

Yes. BIO is 10.3% above its 200-week average of $325.59. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Bio-Rad Laboratories, Inc. growing?

Over the last five fiscal years Bio-Rad Laboratories, Inc.'s revenue grew 0.3% a year and its earnings per share -26.1% a year; over ten years revenue grew 2.5% a year.

Cite this page

Funkfolio, “Bio-Rad Laboratories, Inc. (BIO) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/BIO

Underlying data: Yahoo Finance; company filings with the SEC.